The short answer
Garlic supplements deserve review while taking pazopanib, especially if you have low platelets, bleeding symptoms or other medicines that affect clotting. The concern is precautionary; a direct increase in bleeding from this exact combination has not been measured.
What this answer covers
Oral pazopanib with garlic supplements; exact dose, preparation and other bleeding risks matter.
- Supplement or preparation
- Allium sativum
- Medication ingredient
- pazopanib
Check the exact treatment
This review concerns oral pazopanib tablets containing the hydrochloride salt, with doses expressed as pazopanib. It is used for specified advanced kidney cancer or soft-tissue sarcoma settings. Keep the prescribed fasting schedule and do not crush the tablets.
Why the combination needs review
Pazopanib can cause serious bleeding. Garlic supplements carry a bleeding precaution; concentrated tablets and ordinary seasoning are different exposures. No exact-pair study establishes how much additional risk a particular product creates.
The human evidence is not uniform
A small volunteer trial found no significant platelet aggregation effect from the tested garlic tablets, although some participants reported bleeding at the highest dose. Garlic was compared with aspirin, not tested together with pazopanib, and self-reports do not establish a major-bleeding rate.
Use symptoms and the treatment plan
Show the oncology team the product, dose and other medicines before starting it. Report unusual bruising or persistent bleeding; seek urgent care for major bleeding, black stools or vomiting blood. Do not rely on dose spacing or stop the cancer medicine yourself. Follow the blood-count and monitoring plan.
Evidence and practical considerations
Side effects & toxicity
The drug’s bleeding warning and supplement-specific guidance support conditional review while human counterevidence limits a universal causal claim.
- Exact scope
- Oral pazopanib with garlic supplements; exact dose, preparation and other bleeding risks matter. with RxNorm 714438 IN pazopanib. Current exact oral product: Pazopanib oral hydrochloride tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
- Medication form and route
- Oral
What remains uncertain
- No exact co-use bleeding-outcome trial. Supplement guidance and drug warning are a conditional bridge; proxy tests and different-drug null results retained.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose, duration and other medicines; Individual monitoring plan.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the exact oral formulation.
Severe hepatotoxicity and bleeding warnings; CYP3A interaction precautions; avoid grapefruit products.
How this applies: RxNorm 714438 IN pazopanib. Current exact oral product: Pazopanib oral hydrochloride tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
Exact current oral product source, not a clinical trial of every supplement. Formulation, dose, population and mechanism remain explicit.
Source 2: Original official botanical guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Supplement users.
Supplements may increase bleeding risk; review other medicines and surgery.
How this applies: Conditional bleeding precaution.
No exact pazopanib effect size or event rate.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy volunteers, open-label randomized comparison.
No significant measured platelet aggregation effect; some self-reported bleeding at highest garlic dose.
How this applies: Exact reported preparation, population and endpoints; transfer to pazopanib explicitly limited.
Original body read; small trial and self-report, not major-bleeding rate or pazopanib interaction.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
pazopanib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: d446901617739c5c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.